Lancaster University

Researchers developed a drug, RI-AG03, targeting tau protein clumping in Alzheimer's disease, extending fruit fly lifespan and reducing tau aggregation in cells. Plans for rodent testing precede potential clinical trials, despite past failures of tau-based therapies.

New drug RI-AG03 targets tau protein to prevent Alzheimer’s-related neurodegeneration, inhibiting tau aggregation at two key regions. Preliminary tests on fruit flies and cells show promising results, with plans for rodent trials before clinical testing.

Researchers developed RI-AG03, a drug targeting two Alzheimer's disease 'hotspots' to block tau protein buildup, tested in lab dishes and fruit flies, showing promise in preventing neurodegeneration.

Researchers developed a drug, RI-AG03, targeting both key areas of Tau protein, effective in preventing Tau build-up in lab and fruit fly studies, potentially leading to more effective Alzheimer’s treatments.

Researchers developed RI-AG03, a peptide inhibitor targeting both major Tau protein 'hotspots', preventing neurodegeneration in lab and fruit fly studies, marking a significant step in Alzheimer’s drug development.

Researchers developed a drug, RI-AG03, targeting both key areas of Tau proteins linked to Alzheimer’s, preventing their build-up in lab and fruit fly studies. The drug aims to address Tau aggregation, potentially leading to more effective treatments for neurodegenerative diseases.

A drug, RI-AG03, developed by an international team led by Lancaster University, targets both major aggregation-promoting 'hotspots' of the tau protein, key to Alzheimer's Disease. Effective in preventing tau buildup in lab and fruit fly studies, it could lead to more targeted and safer treatments for neurodegenerative diseases.

Researchers developed RI-AG03, a peptide inhibitor targeting both major Tau protein 'hotspots', effective in preventing Tau build-up in lab and fruit fly studies, potentially paving the way for Alzheimer's treatments.